Skip to main content

BMO Capital Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Sat Mar 7, 6:30AM CST

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Vertex Pharmaceuticals, with a price target of $600.00. The company’s shares closed yesterday at $460.82.

Claim 70% Off TipRanks Premium

According to TipRanks, Seigerman is a 5-star analyst with an average return of 9.0% and a 52.88% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Disc Medicine, Novo Nordisk, and Eli Lilly & Co.

Currently, the analyst consensus on Vertex Pharmaceuticals is a Strong Buy with an average price target of $550.70, a 19.50% upside from current levels. In a report released on February 19, Evercore ISI also maintained a Buy rating on the stock with a $530.00 price target.

See the top stocks recommended by analysts >>

Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.23 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $2.91 billion and had a net profit of $913 million

Read More on VRTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).